Form 4: CRISPR Therapeutics Director Granted 13,000 Stock Options

Briggs Morrison, a Director at CRISPR Therapeutics AG, was granted 13,000 stock options with an exercise price of $38.57, aligning his interests with shareholder value.

Summary

• Briggs Morrison, a Director of CRISPR Therapeutics AG (CRSP), was granted 13,000 stock options on June 5, 2025.
• The exercise price for these options is $38.57 per common share.
• The options will vest 100% in 12 equal monthly installments, commencing on June 30, 2025.
• The final installment will vest on the earlier of the one-year anniversary of the grant date (June 5, 2026) or the date of the 2026 Annual General Meeting of Shareholders.
• The stock options have an expiration date of June 5, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns management interests with shareholders, but it is a routine compensation disclosure rather than a significant operational or financial announcement.

Positives

• The grant of stock options to a director aligns their financial interests directly with the long-term performance and shareholder value of CRISPR Therapeutics.
• Equity compensation is a standard practice that incentivizes directors to contribute to the company's growth and success.

Future Outlook

The vesting schedule of the stock options indicates a future alignment of the director's compensation with the company's performance over the next year, encouraging sustained engagement and contribution.

Industry Context

The grant of stock options is a common and widely accepted form of executive and director compensation within the biotechnology and pharmaceutical industries, designed to attract and retain talent while aligning leadership interests with long-term shareholder value.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotech sector like CRISPR Therapeutics.
• The specific terms, such as the exercise price relative to the market price at grant and the vesting schedule, are typical for equity incentive plans aimed at long-term retention and performance alignment.

Corporate Governance

Related Party Transactions

• The stock option grant to Briggs Morrison, a Director, constitutes an insider transaction, which is a standard form of compensation for company leadership.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value, potentially leading to better long-term performance.
• Employees: While not directly impacting all employees, such compensation practices can reflect the company's overall approach to incentivizing its leadership.

Next Steps

• The granted stock options will begin vesting in monthly installments starting June 30, 2025.
• The director will acquire beneficial ownership of common shares as the options vest over the subsequent 12 months.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Stock Option Grant, Director Compensation, Insider Transaction, SEC Form 4, Equity Compensation, Biotechnology